HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) has filed for Chapter 11 bankruptcy protection, as stated in a regulatory filing with the SEC. 

The company's voluntary petition (Case No. 23-10732) was submitted to the United States Bankruptcy Court for the District of Delaware on June 5, 2023. As part of the bankruptcy proceedings, HTG Molecular Diagnostics will continue its operations as a "debtor-in-possession" under the supervision of the Court and in compliance with the relevant provisions of the Bankruptcy Code and court orders. 

$HTGM was trading at $0.88 in after-hours, reflecting a decrease of $0.80 or 47.55%.

Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company focused on developing oncolytic immunotherapies for the treatment of cancer, received a price target increase from $50 to $51 by HC Wainwright & Co. 

Despite closing at $22.60 on Monday, this upward revision suggests a potential upside of $28.40 (+125.66%) for $REPL, based on HC Wainwright & Co.'s analysis.

HOOKIPA Pharma Inc. (Nasdaq: HOOK), a clinical-stage biopharmaceutical company specializing in immunotherapeutics and gene therapies, had its price target raised from $2 to $2.25 by Morgan Stanley. 

With a closing price of $1.16 on Monday, this adjusted price target indicates a potential upside of $1.09 (+94.03%) for $HOOK, according to Morgan Stanley's view.

GoDaddy Inc. (NYSE: GDDY), a leading provider of domain registration and web hosting services, was initiated with a Sector Perform rating and a price target of $80 by RBC Capital Markets. 

Despite closing at $72.55 on Monday, this initiation suggests a potential upside of $7.45 (+10.26%) for $GDDY, according to RBC Capital Markets' assessment.

It is important to note that the potential upsides mentioned above are derived from the assessments of HC Wainwright & Co., Morgan Stanley, and RBC Capital Markets. These estimates provide informative viewpoints within the investment landscape and should be considered alongside market dynamics and individual investment strategies.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)